Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 16 to 24 of 24 results for imatinib

  1. Past appeals and decisions

    May 2010 TA251 Leukaemia (chronic myeloid) - dastatinib, nilotinib, imatinib (intolerant, resistant) (including partial review of TA70)...

  2. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA728

  3. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  4. Committee C members

    Hammersmith Hospital in London. He treated the first UK patients to receive imatinib and continues to be closely involved with ongoing...

  5. Avapritinib for treating advanced systemic mastocytosis (TA1012)

    Evidence-based recommendations on avapritinib (Ayvakyt) for treating advanced systemic mastocytosis in adults.

    Technology appraisal guidance
    Published
    6 November 2024
    View recommendations

    Sections for TA1012

  6. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  7. Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (TA196)

    This guidance has been replaced by NICE technology appraisal guidance 326.

    Technology appraisal guidance
    Published
    25 August 2010

  8. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance (TA241)

    This guidance has been updated and replaced by NICE technology appraisal guidance 425.

    Technology appraisal guidance
    Published
    13 January 2012

  9. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

    Technology appraisal guidance
    Published
    25 April 2012